GordonMD Global Investments® LP (US) and Partners Investments Co., Inc. (South Korea) Announce Biopharmaceutical Investment Collaboration

BEVERLY HILLS, Calif. & SEOUL, South Korea--(BUSINESS WIRE)--GordonMD Global Investments^® LP (“GordonMD”), a US-based investment manager focused exclusively on global public and private biopharmaceutical investments, and Partners Investment Co., Ltd., (“Partners”), a South Korean-based investment firm with more than 20 years experience investing in healthcare and life sciences have agreed to enter into a joint investment collaboration.

This venture leverages the combined knowledge and resources of two firms with decades of investing experience in both public and private growth companies, extensive relationships with industry participants and management teams plus practical medical training.

“Collaborating with Partners positions us to pursue and invest in breakthrough therapies not only in the US but also in South Korea, a country increasingly active in the biopharmaceutical space,” said Craig Gordon, MD, Founder and Chief Executive Officer of GordonMD. “We are eager to identify and help nurture innovation and growth among pre-clinical and clinical biopharmaceutical companies,” he added.

“This venture could be a groundbreaking initiative for the expansion of promising South Korean biotech companies into the U.S. market. We believe this partnership will serve as a bridge connecting biotech companies in both countries and foster global innovation,” stated Jae An, PhD, Managing Director of Partners.

About GordonMD^® Global Investments^® LP
GordonMD Global Investments^® LP was founded in 2021 by Craig Gordon, MD, a licensed physician with more than 14 years of buy-side experience managing global biopharmaceutical portfolios. The firm focuses on identifying differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan.

About Partners Investment Co., Ltd.
Partners Investment Co., Ltd., a leading venture capital firm based in Seoul, South Korea, was established in 2000. Since its inception, the firm has raised $870 million in capital, primarily from esteemed national and governmental limited partners (LPs), including the National Pension Service, Korea Development Bank, Korean Federation of Community Credit Cooperatives, and Korea Teachers’ Credit Union. Approximately 40% of its investments have been directed toward the Healthcare and Life Sciences sector.